Certain Medications Become Cheaper in Serbia with Prescription

Starting today, Serbian citizens will benefit from reduced co-payments for certain prescription medications, as new provisions of the Rulebook on the List of Medications of the Republic Health Insurance Fund come into effect. This change specifically impacts two crucial groups of drugs. Firstly, patients receiving oral anticoagulants, prescribed to prevent strokes and blood clots, will see a significant price reduction. The monthly cost for these 16 medications will decrease from a previous range of 1,700 to 6,000 dinars to between 600 and 1,100 dinars per dose. Secondly, modern SGLT2 inhibitors, used in the treatment of heart failure and diabetes, will also become more affordable. Although these drugs have a standard patient co-payment of fifty percent, state subsidies mean that patients with a prescription from their chosen doctor will now pay approximately 700 dinars per package. While these reduced rates for existing medications are effective immediately, the introduction of innovative therapies will occur in phases. Starting August 26, 2026, treatments for skin and immune diseases, including psoriasis, will become available. Subsequently, another group of medications will be accessible by August 31, followed by oncological drugs entering the market on September 30, 2026.